Blocking the VEGFR, PDGFR, and FGFR signaling pathways is an effective tumor therapy to inhibit tumor growth (9) To date, several trials of nintedanib in NSCLC treatment have been reported (Table 1), such as the LUME-lung 1 (10) and LUME-lung 2 trials (11), and the VARGDO study (14). The gene discussed is KDR; the disease is non-small cell lung carcinoma.